Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

Tremfya (guselkumab) is a brand-name drug approved to treat ulcerative colitis (UC). This article covers topics such as side effects, dosage, and how Tremfya works. Tremfya is available as a ...

Johnson & Johnson (NYSE: JNJ) announced significant advancements in the treatment of moderately to severely active ulcerative colitis (UC) with its drug TREMFYA® (guselkumab). The Phase 3 ASTRO ...

Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate to severe UC patients.

Johnson & Johnson (JNJ) said on Friday that its late-stage study of TREMFYA as an induction therapy for adults with ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

US healthcare giant Johnson & Johnson has announced data from the Phase III ASTRO study of Tremfya (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ...

(RTTNews) - Johnson & Johnson (JNJ) reported data from the Phase 3 ASTRO study of TREMFYA subcutaneous induction therapy in adults with moderately to severely active ulcerative colitis. The ...

Johnson & Johnson announced data from the Phase 3 ASTRO study of TREMFYA subcutaneous, SC, induction therapy in adults with moderately to ...

Findings were announced from a phase 3 trial evaluating guselkumab subcutaneous (SC) induction therapy in patients with moderately to severely active ulcerative colitis (UC). Study participants ...

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than Humira’s 20% at the same time point.